Development of a 2′,4′-BNA/LNA-based siRNA for Dyslipidemia and Assessment of the Effects of Its Chemical Modifications In Vivo

Development of a 2′,4′-BNA/LNA-based siRNA for Dyslipidemia and Assessment of the Effects of Its Chemical Modifications In Vivo

Recent advances in RNA interference (RNAi)-based drug development have partially allowed systemic administration of these agents in vivo with promising therapeutic effects. However, before chemically modified small-interfering RNAs (siRNAs) can be applied clinically, their in vivo effects should be...

Full description

Bibliographic Details
Main Authors: Shunsuke Wada, Satoshi Obika, Masa-Aki Shibata, Tsuyoshi Yamamoto, Moeka Nakatani, Tetsuji Yamaoka, Hidetaka Torigoe, Mariko Harada-Shiba
Format: Article
Language:English
Published: Elsevier 2012-01-01
Series:Molecular Therapy: Nucleic Acids
Subjects:
siRNA
2′4′-BNA/LNA
chemical modification
dyslipidemia
innate immune response
Online Access:http://www.sciencedirect.com/science/article/pii/S2162253116300993

Internet

http://www.sciencedirect.com/science/article/pii/S2162253116300993

Similar Items